Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Inhalation powder spray for treating respiratory diseases such as chronic obstructive pulmonary disease and asthma

A technology for chronic obstructive pulmonary and respiratory diseases, applied to respiratory diseases, organic active ingredients, medical preparations containing active ingredients, etc., can solve problems such as poor room temperature stability, low bioavailability, and low inhalation efficiency. It achieves the effect of convenient taking, simple processing equipment and alleviating irritation

Inactive Publication Date: 2009-05-13
李虎山
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This patented technology involves making small particles called ivoryoponium bridepium that dissolve quickly when taken up by lung tissue cells like coughing mucous membranes. These tiny particles have been found effective against chronic bronchitis caused by viruses such as rhinovirus type 2 virus. They were able to enter blood vessels around the heart muscle causing inflammations similar symptoms to those seen during astrocytoma cancer treatments.

Problems solved by technology

This patented technical problem addressed in this patents relates to improving upon existing drugs used to treat pulmonary conditions like astrocytoma lung cancer due to its slow metabolism and potential negative impacts on healthy tissues.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Inhalation powder spray for treating respiratory diseases such as chronic obstructive pulmonary disease and asthma

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] The prescription composition of 0.018mg / 0.09mg ipratropium bromide and salbutamol sulfate inhalation powder mist (taking the capsule type as an example) is as follows: 1,000,000 capsules, which contain

[0029] Ipratropium Bromide 15g

[0030] Salbutamol sulfate 50g

[0031] Lactose 2.00kg

[0032] Preparation method: at room temperature, mix 15g ipratropium bromide and 50g salbutamol sulfate and crush to an average particle size of 2μm; take the dried lactose and crush it to an average particle size of 2μm, mix it with the above powder, and then mix the powder Fill it into a filling machine to make a powder aerosol.

Embodiment 2

[0034] The prescription composition of 0.5mg / 0.05mg ipratropium bromide and salbutamol sulfate inhalation powder mist (taking the capsule type as an example) is as follows: 1,000,000 capsules, which contain

[0035] Ipratropium Bromide 500g

[0036] Salbutamol sulfate 50g

[0037] Lactose 2.00kg

[0038] Preparation method: Mix 500g ipratropium bromide and 50g salbutamol sulfate at room temperature, and crush it to an average particle size of 2μm; take the dried lactose and crush it to an average particle size of 3μm, mix it with the above powder, and then mix the powder. Fill it into a filling machine to make a powder mist.

Embodiment 3

[0040] The prescription composition of 0.25mg / 0.05mg ipratropium bromide and salbutamol sulfate inhalation powder mist (taking the capsule type as an example) is as follows: 1,000,000 capsules, which contain

[0041] Ipratropium Bromide 250g

[0042] Salbutamol sulfate 50g

[0043] Lactose 2.00kg

[0044] Preparation method: at room temperature, mix 250g of ipratropium bromide and 50g of salbutamol sulfate and pulverize to an average particle size of 2μm; take the dried lactose and pulverize it to an average particle size of 2μm, mix with the above powder, and then the powder Fill it into a filling machine to make a powder mist.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses powder inhalation for treating respiratory system diseases such as chronic obstructive pulmonary diseases and asthma. The powder inhalation comprises all the tautomer, enantiomer, stereoisomer, acid anhydride, acid addition salt, basic salt, solvolyte, analogue and derivative of a first active ingredient - ipratropium, a second active ingredient - salbutamol, and one or more pharmaceutically acceptable carriers; wherein other pharmaceutically acceptable salt of salbutamol is selected from other salt of organic acid of salbutamol sulfate or salbutamol, and the mass ratio of the first active ingredient and the second active ingredient is 1:10 to 15:1; according to the ratio of the prescription, uniformly blending the ipratropium and the salbutamol and crushing to an average grain size of 1 to 5 Mum, crushing the dried carrier to an average grain size of 1 to 5 Mum, and filling the uniformly blended powder into a filling machine to produce the powder inhalation. The powder inhalation can directly act on the affected part, the efficacy presents quickly, and the use is convenient.

Description

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Owner 李虎山
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com